Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab. [PDF]
Kuwano A +6 more
europepmc +1 more source
Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. [PDF]
Wu C, Wei T, Ye X, Dong Z, Chen X.
europepmc +1 more source
Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis. [PDF]
Wu S, Wang C, Liu S.
europepmc +1 more source
Bacterial extracellular vesicles as emerging platforms to combat multidrug-resistant bacterial infections: Mechanisms, therapeutic applications, and future prospects. [PDF]
Zhou Z +5 more
europepmc +1 more source
Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. [PDF]
Suenaga M +5 more
europepmc +1 more source
Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma. [PDF]
Wysocki PT, Chmiel P, Jassem J, Kraj L.
europepmc +1 more source
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2. [PDF]
Goto Y +19 more
europepmc +1 more source
Balloon-Expandable Versus Self-Expanding Prostheses for Transcatheter Treatment of Patients With Low-Flow, Low-Gradient Aortic Stenosis. [PDF]
Ferruzzi GJ +30 more
europepmc +1 more source
On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. [PDF]
Tajiri K +5 more
europepmc +1 more source

